New data suggests current lung cancer screening protocols are putting too many patients at risks
Industry Buzz
We are seeing advanced cancers in individuals who did not meet screening thresholds. Smoking history is not the whole story... We need data on non-smoking risk factors integrated into guidelines so clinicians are confident in expanding screening.
—Alok Mohta, MD
Lung cancer screening strategy is at a crossroads. New evidence suggests current criteria may miss a large fraction of cases. This has major implications for your patients and practice.
A November 2025 STAT analysis shows US screening eligibility based on age and smoking history excludes many people who ultimately develop lung cancer.[]
Broadening to age alone (40 to 85) could detect about 94% of cancers and prevent over 26,000 deaths per year, with low-dose CT scans exposing patients to minimal radiation and costs lower than with many other screening programs. Commenting on the study, board-certified physician Alok Mohta, MD, said, “We are seeing advanced cancers in individuals who did not meet screening thresholds. Smoking history is not the whole story.”
What the latest data says
According to emerging clinical data, non-tobacco factors are gaining prominence:
Genetic predisposition: EGFR and other less common mutations contribute to lung cancer in never-smokers, particularly among women and Asian populations.[]
Air pollution: A recent worldwide epidemiologic analysis shows fine-particulate pollution strongly correlates with lung cancer incidence, independent of smoking.[]
Socioeconomic determinants: Delayed diagnosis and unequal access to screening disproportionately affect historically excluded groups.[]
Racial bias in screening criteria: A Vanderbilt analysis found standard eligibility rules disproportionately exclude Black smokers who go on to develop lung cancer.[]
Dr. Mohta elaborates, “Clinically, these insights suggest your high-risk patient definition should go beyond heavy smoking history and age. Consider broader use of risk calculators that integrate demographic, environmental, and genetic variables.”
The NCCN guidelines already provide such tools.[]
Takeaways for the clinic
Practical points for your clinic should include:
Reevaluate screening thresholds for patients with significant environmental exposure even without heavy smoking history.
For patients excluded by standard criteria but with strong risk markers (family history, air pollution exposure, prior lung disease), discuss personalized screening benefits and limitations.
Be aware of overdiagnosis. Early detection increases lead time but does not always improve mortality without affecting disease course.
Barriers remain. Screening uptake is low across multiple health systems due to cost, infrastructure, and awareness gaps.[]
“We need data on non-smoking risk factors integrated into guidelines so clinicians are confident in expanding screening," Dr. Mohta tells MDLinx.
AI tools are under study to enhance risk stratification and image interpretation. Preliminary research shows potential in predicting malignancy from CT patterns and genomic data, though clinical adoption hurdles remain.[]
For your practice, staying current with evolving guidelines and evidence on non-traditional risk predictors could improve early detection and shift outcomes for patients who fall outside legacy risk brackets.
Read Next: The first-ever guidelines for AI use in oncology are now available